A Phase 2 interventional study of REGN2477+REGN1033 and Matching placebo in Sporadic Inclusion Body Myositis, sponsored by Regeneron Pharmaceuticals. Withdrawn. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-29.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to evaluate the efficacy of REGN2477+REGN1033 in combination on total lean mass, as measured by Dual-energy X-ray absorptiometry (DXA) in patients with sporadic inclusion body myositis (sIBM).
The secondary objectives of the study are:
65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.
Browse Myositis, Inclusion Body studies →Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol Inclusion/Exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single, sequential, repeat-dose IV or matching placebo
Drug: REGN2477+REGN1033
Single, sequential, repeat-dose IV
Drug: Matching placebo
Drug pages: Garetosmab · Trevogrumab
Single, sequential, repeat-dose Intravenous (IV) or matching placebo
Single, sequential, repeat-dose Intravenous (IV)
Percent change in total lean mass as measured by dual-energy X-ray absorptiometry (DXA)
Time frame: Up to Week 20
Change in the Inclusion Body Myositis-Functional Rating Scale (IBM-FRS)
Time frame: Up to Week 26
Change in the Sporadic inclusion body myositis (sIBM) Physical Functioning Assessment (sIFA)
Time frame: Up to Week 26
Incidence and severity of treatment-emergent adverse events (TEAEs)
Time frame: Up to Week 30
Percent change in total and regional body composition (including lean mass and fat mass) as measured by DXA
Time frame: Up to Week 30
Absolute change in total and regional body composition (including lean mass and fat mass) as measured by DXA
Time frame: Up to Week 30
Change in the 1-repetition maximum (1-RM) chest press strength
Time frame: Up to Week 26
Change in hand-grip strength as measured by dynamometry
Time frame: Up to Week 26
Change in distance walked in the 6-minute walk test (6MWT)
Time frame: Up to Week 26
Change in time to complete the 10-meter walk test (10MWT)
Time frame: Up to Week 26
Change in instrumented stair climb power
Time frame: Up to Week 26
Change in instrumented, sensor-based sit-to-stand test time
Time frame: Up to Week 26
Change in fear of falling as measured via the Falls Efficacy Scale-International (FES-I)
Time frame: Up to Week 30
Change in Patient Global Impression of Severity assessments (PGIS/PGIC)
Time frame: Up to Week 30
Change in Patient Global Impression of Change Items assessments (PGIS/PGIC)
Time frame: Up to Week 30
Change in Clinician Global Impression of Severity assessments (CGIS/CGIC)
Time frame: Up to Week 30
Change in Clinician Global Impression of Change Items assessments (CGIS/CGIC)
Time frame: Up to Week 30
Change in 36-item Short Form Health Survey (SF-36), including the Physical Function Items (PF-10) and the Vitality Scale of the SF-36
Time frame: Up to Week 30
Change in Thigh muscle volume as measured by MRI (sub-study)
Time frame: Up to Week 30
Frequency of falls and near-falls as measured by the Hopkins Falls Grading Scale
Time frame: Up to Week 30
Pharmacokinetics (PK) profile of REGN2477
Assessed via serum concentration of REGN2477 over time
Time frame: Up to Week 30
Pharmacokinetics (PK) profile of REGN1033
Assessed via serum concentration of REGN1033 over time
Time frame: Up to Week 30
Immunogenicity of REGN2477+REGN1033
As determined by the presence or absence of anti-drug antibodies (ADA)
Time frame: Up to Week 30
No study locations are listed for this record.
Start is estimated for Feb 2019; primary completion for Aug 2020, 18 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Garetosmab · Trevogrumab